About 60-70% of the drugs synthesized are poorly soluble and comes under BCS Class-II&IV. Now it is a challenging situation during the development of different dosage forms for pharmaceutical industries because solubility of the drug is the rate limiting step. Based on the solubility, the dissolution, bioavailability & therapeutic effect is dependent. To overcome this consequence a novel technique -Liquisolid compact is used by dissolving the poorly soluble drug in a non-volatile solvent that improves wettability & decreases the surface tension and ensures drug molecular dispersion in the formulation to increase the solubility of the drug. This admixture of drug loaded solution is blended with carrier adsorption & coating material (adsorption) that has free flowing and compressible powder properties.
INTRODUCTION
Numerous potent lipophilic drugs show low oral bioavailability due to their poor aqueous solubility properties that falls under BCS-II-low solubility and high permeability¹. However low solubility and dissolution rate are main rate limiting factors². As per bioavailability is concerned, a drug is poor bioavailability is one with 1. Poor aqueous solubility or slow dissolution rate in the biological fluid.
2. No proper partition coefficient and thus poor permeation through the biomembrane.
3. Less stability of the dissolved drug at the physiological P H .
There are few approaches to overcome the bioavailability problem as listed below
A. Modification of formulation, manufacturing process/ changing the Physiochemical properties of drug according to pharmaceutical approach.
B. Alteration of chemical structure according to pharmacokinetic approach.
C. Route of drug administration may be changed from oral to parenteral route according to biological approach.
As per the pharmacokinetic approach, chemical structure modification having number of draw backs. It is expensive and time consuming and also requires clinical study for longer time and the new chemical entity suffer from another pharmacokinetic disorders.
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Finally the pharmaceutical approach will be dealt here with.
The attempts whether optimizing the formulation, manufacturing process or drug physico-chemical properties that are mainly aimed at enhancement of dissolution rate as it is the major rate limiting step in the absorption of most drugs³. When the largest dose of a drug substance is soluble in lesser than 250 ml water such drugs are consider as highly soluble. Drug with solubility below 0.1 mg / ml or 10 mg/ml faces significant obstacles 4 .
The drug dissolution rate is directly proportional to solubility as per Noyes whitney equation and therefore solubility of a drug substance is a major factor. They are several methods to enhance the solubility, surface area and dissolution rate of poorly soluble drugs 5 . They are as follows: Micronization is a common method to increase surface area but alter the flow property when drugs are encapsulated or tableted 6 . In complexation with cyclodextrins maximum drug loaded is relatively low and also depends upon the cavity of the dextrin 7, 8 . Solid dispersion preparation requires special equipments likes spray dryer or fluid bed dryer 9 . Each and every technique has advantages and disadvantages. So to overcome the solution a novel technique-liquisolid compaction technology is developed to increase the solubility and dissolution rate of poorly soluble drugs.
Liquisolid system:
Liquid solid systems are powdered forms of liquid medication that exhibit acceptable or desirable flowability and compressibility properties. That term liquid medication refers to a solution or a suspension of a water insoluble drug in non-volatile solvent.
Based on the type of liquid medication, liquisolid systems may be classified into three subgroups: 1) Powdered drug solutions 2) Powdered drug suspensions
3) Powdered liquid drugs
The first two may be produced from the conversion of drug solutions (e.g. Prednisolone solution in propylene glycol) or drug suspensions (e.g. gemfibrozil suspension in Polysorbate 80) and the latter from the formulation of liquid drugs (e.g. clofibrate, valproic acid, liquid vitamins, etc.) into liquisolid systems 10 .
Based on the formulation technique used, liquisolid systems may be classified into two categories, namely,
1) Liquisolid compacts
2) Liquisolid Microsystems.
Liquisolid compacts are prepared by using the below method to produce tablets or capsules, whereas the liquisolid Microsystems are based on a new concept which employs similar methodology combined with the inclusion of an additive, e.g., polyvinylpyrrolidone (PVP) in the liquid medication which is incorporated into the carrier and coating materials to produce an acceptably flowing admixture for encapsulation 11 . The technique of liquisolid compaction has been used successfully to improve the invitro release of poorly soluble drugs such as piroxicam 12 , progesterone 13 , repaglinide 14 , furesomide 15 .
Components of liquisolid compaction formulation 1. Poorly insoluble drugs:
Examples: Bromohexine hydrochloride, Indomethacin, Prednisolone & Aceclofenac.
This technique is successfully applied for low dose BCS class II and class IV drugs which are poorly water soluble and have slow dissolution rate 16 . Non volatile solvents improve wetting properties where liquid vehicle acts as wetting agent or surface active agent. Therefore interfacial tension decreases between media and surface of the drug or decreases the contact angle and increases the surface area in turn increases the solubility 17 .
Non volatile solvents

Carrier:
Examples: starch, lactose, sorbitol, microcrystalline cellulose.
Principle of carrier: Carrier involves in the sorption process of liquid medication that improves surface area due to adsorption of porous particle and also having adsorption property and matted fibers in interior contribute in liquid medication 18 .
Coating material:
Examples: Pre formulation studies of liquisolid compacts 
Determination of drug solubility in different non volatile solvents:
Saturated solutions are prepared by adding excess of drug to non volatile solvents and shaking them on a shaker for 48 hours and the solutions are filtered by whatman filter paper and analyzed by spectrophotometer and the best solubility solvent is selected 22 .
Angle of slide determination:
Weighed amount of carrier is placed at one end of metal plate with a polished surface and gradually raised till the plate becomes angular to the horizontal at which powder is about to slide. It is used to measure the flow properties of powders. The angle of 33° is optimum for flow of powder.
Flowable liquid retention potential (Φ value) determination:
It is defined as the maximum weight of liquid that can be retained per unit powder material in order to produce and acceptably flowing liquid/powder admixture. This Φ -value of powders may be determined using a new procedure-liquisolid flowability (LSF) test. The Ø value is used to calculate excipient quantities. Equation for this is as follows:
Where Ø and Ø are the constant Ø values of carrier and coating materials, respectively. By calculating Lf and W, can calculate the amount of Q and q required for liquisolid systems.
Calculation of liquid loading factor (Lf)):
It is defined as the ratio of weight of liquid medication (w) to weight of carrier material (Q). Different concentrations of nonvolatile solvents are taken and the drug is dissolved and the carrier coating material is added and blended 23 .
Lf=W/Q
W=ratio of weight of liquid medication Q= weight of carrier material
The liquid load factor that ensures acceptable flowability (Lf), and can be measured by:
Lf= (1/R)
Liquisolid compressibility test (LSC):
It is developed to determine Ψ values and involves steps such as preparing carrier coating material admixture systems, preparing several uniform liquid/powder admixtures to tablets, determining average hardness, measuring of average liquid content of crushed tablets, as well as determining plasticity, sponge index and Ψ
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Preparation of Liquid Solid Compacts
This method involves first a mathematically calculated amount of pure drug weighed and dissolved in the solvent in a molecularly dispersed state. For attaining good flow properties trial and error methods were used i.e. changing the carrier: coating material ratio from 50:1 The flow properties of the liquid solid system are determined by angle of repose, carr's index and hausner ratio.
Scanning electron microscopy:
Scanning electron microscopy is used to assess the morphological characteristics of the poorly soluble drugs -carrier system and liquid solid compact. The sample is mounted on double sided adhesive carbon tape on brass stubs and analyzed and also confirms the drug is totally solubilized in liquid solid system and this ensures the complete solubility.
X-Ray Powder diffraction (XRD) studies:
X-ray powder diffraction studies conducted to pure drug, liquisolid physical mixture. These samples are exposed to Cu-Kα radiation at a scan rate of 1.50 / min over the 2θ range of 4-400 0 C. Generally, disappearance of characteristic peaks of drug in the liquisolid formulation and retaining peaks of carrier material is observed. This indicates that drug gets converted to amorphous form or in solubilized form in the liquisolid formulation.
Differential Scanning Calorimetry (DSC):
To determine the interaction between excipients used in the formulation. This will also indicate success of stability studies. If the characteristic peak for the drug is absent in the DSC thermogram, there is an indication that the drug is in the form of solution in liquisolid formulation and hence it is molecularly dispersed within the system 36 .
Post compression evaluation:
Hardness: hardness of the tablet is determined by Monsanto hardness tester and Pfizer tester. It is expressed in Kg/cm².
Friability:
In friability test, samples are counted and weighted then tumbled in rotating drums with baffles, when the process is stopped; samples are moved out from the instrument, wiped-off dust and weighted again. The difference between the weight before and after the process is determined as Friability and should not exceed 1%, which is considered an ideal percentage.
In-vitro dissolution studies:
Generally dissolution studies are carried out using dissolution test apparatus USP -II at 37°±5°C. Many researches reveal that at low drug concentration in liquid medication, more rapid release rates are observed 37 .
Invivo evaluation of liquisolid powder or tablets:
The improvement in oral bioavailability is confirmed by estimating the pharmacokinetic parameters in various animals such as rabbit, beagle dog and the results are compared to the pure drug and marketed tablets 38 .
Merits
1. Bio-Pharmaceutical classification class II drugs with high permeability, slightly or very slightly water soluble
